Phase 3 Recruiting Academic/Other
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radi…
Sponsor: NRG Oncology
NCT ID: NCT04852887
Sites in South Carolina: - Saint Joseph's/Candler - Bluffton Campus — Bluffton, South Carolina
- Medical University of South Carolina — Charleston, South Carolina
- McLeod Regional Medical Center — Florence, South Carolina
- Tidelands Georgetown Memorial Hospital — Georgetown, South Carolina
- The Radiation Oncology Center-Hilton Head/Bluffton — Hilton Head Island, South Carolina
Phase 3 Recruiting Academic/Other
This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complet…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06876714
Sites in South Carolina: - Beaufort Memorial Hospital — Beaufort, South Carolina
- Prisma Health Cancer Institute - Spartanburg — Boiling Springs, South Carolina
- Medical University of South Carolina — Charleston, South Carolina
- Prisma Health Cancer Institute - Easley — Easley, South Carolina
- Tidelands Georgetown Memorial Hospital — Georgetown, South Carolina
Phase 3 Recruiting NIH
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 nega…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06058377
Sites in South Carolina: - Saint Joseph's/Candler - Bluffton Campus — Bluffton, South Carolina
- Prisma Health Cancer Institute - Spartanburg — Boiling Springs, South Carolina
- Roper Hospital — Charleston, South Carolina
- Charleston Oncology - Roper — Charleston, South Carolina
- Bon Secours Saint Francis Hospital — Charleston, South Carolina
Phase 3 Recruiting Academic/Other
NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and …
Sponsor: NRG Oncology
NCT ID: NCT06748222
Sites in South Carolina: - Beaufort Memorial Hospital — Beaufort, South Carolina
- Prisma Health Cancer Institute - Spartanburg — Boiling Springs, South Carolina
- Medical University of South Carolina — Charleston, South Carolina
- Prisma Health Cancer Institute - Easley — Easley, South Carolina
- MUSC Health Florence Medical Center — Florence, South Carolina
Phase 3 Recruiting Industry
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who…
Sponsor: AstraZeneca
NCT ID: NCT05952557
Sites in South Carolina: - Research Site — Charleston, South Carolina
- Research Site — Greenville, South Carolina
- Research Site — Rock Hill, South Carolina
- Research Site — Spartanburg, South Carolina
Phase 2 Recruiting NIH
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in South Carolina: - Prisma Health Cancer Institute - Spartanburg — Boiling Springs, South Carolina
- Prisma Health Richland Hospital — Columbia, South Carolina
- Prisma Health Cancer Institute - Easley — Easley, South Carolina
- Saint Francis Hospital — Greenville, South Carolina
- BI-LO Charities Children's Cancer Center — Greenville, South Carolina
Phase 2 Recruiting Academic/Other
This is an open label, multicenter, single arm phase II study to evaluate the efficacy and safety of ribociclib and ET in patients with locoregional recurrence of HR-positive, HER2-negative breast cancer.
Sponsor: Oana Danciu
NCT ID: NCT05467891
Sites in South Carolina: - Medical University of South Carolina — Charleston, South Carolina
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to establish the recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD), safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of ORIC-114 as a Single Agent or in Combination…
Sponsor: ORIC Pharmaceuticals
NCT ID: NCT05315700
Sites in South Carolina: - Spartanburg Regional Healthcare System — Spartanburg, South Carolina
Phase 2 Recruiting Academic/Other
This is a single-arm Phase II study to assess the efficacy of a 12-18 week neoadjuvant carboplatin, paclitaxel, and pembrolizumab (CPP) regimen in a response-adaptive manner for triple-negative breast cancer (TNBC) patients who are ineligi…
Sponsor: Medical University of South Carolina
NCT ID: NCT06845319
Sites in South Carolina: - Medical University of South Carolina — Charleston, South Carolina
Phase 1 Recruiting Industry
The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.
Sponsor: SystImmune Inc.
NCT ID: NCT05983432
Sites in South Carolina: - PRISMA Health/ITOR — Greenville, South Carolina
Phase 1 Recruiting Industry
A phase 1a/1b, multicenter, open-label, dose escalation/expansion, multiple-dose study to evaluate the safety and activity of DR-0202 in patients with locally advanced or metastatic, relapsed or refractory carcinomas
Sponsor: Dren Bio
NCT ID: NCT06999187
Sites in South Carolina: - Dren Investigational Site — Greenville, South Carolina
Phase 1 Recruiting Academic/Other
This is a randomized placebo controlled partially blinded window of opportunity trial. A maximum of 84 patients with invasive breast cancer will be enrolled. Patients will be randomized 2:2:1:1 to either CBD low dose, CBD high dose, matchi…
Sponsor: Medical University of South Carolina
NCT ID: NCT06148038
Sites in South Carolina: - Medical University of South Carolina — Charleston, South Carolina
NA Recruiting Network
The purpose of this study is to evaluate feasibility and acceptability of completing PROs among AYAs randomized to Choice PRO vs Fixed PRO.
Sponsor: Eastern Cooperative Oncology Group
NCT ID: NCT05108298
Sites in South Carolina: - AnMed Health Cancer Center — Anderson, South Carolina
- Saint Joseph's/Candler - Bluffton Campus — Bluffton, South Carolina
- Prisma Health Cancer Institute - Spartanburg — Boiling Springs, South Carolina
- Prisma Health Cancer Institute - Easley — Easley, South Carolina
- Gibbs Cancer Center-Gaffney — Gaffney, South Carolina
Recruiting Industry
The FLEX Registry will be implemented to operate as a large-scale, population based, prospective registry. All patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing on a primary breast tumor are eligible …
Sponsor: Agendia
NCT ID: NCT03053193
Sites in South Carolina: - Roper St. Francis Physician Partners - Breast Surgery — Charleston, South Carolina
- Tidelands Health Coastal Carolina Breast Center — Georgetown, South Carolina
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in South Carolina: - Massive Bio SYNERGY-AI site — Greenville, South Carolina